• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatric Infectious Disease Journal: Postexposure Prophylaxis for Influenza in Pediatric Wards Oseltamivir or Zanamivir After Rapid Antigen Detection

tetano

Editor, Senior Moderator
Pediatric Infectious Disease Journal:
November 2012 - Volume 31 - Issue 11 - p 1119?1123
doi: 10.1097/INF.0b013e318260265a
Original Studies
Postexposure Prophylaxis for Influenza in Pediatric Wards Oseltamivir or Zanamivir After Rapid Antigen Detection

Shinjoh, Masayoshi MD, PhD*?; Takano, Yaoko RN, MSN, CNS?; Takahashi, Takao MD, PhD*?; Hasegawa, Naoki MD, PhD?; Iwata, Satoshi MD, PhD?; Sugaya, Norio MD, PhD?
Collapse Box
Abstract

Background: Postexposure prophylaxis (PEP) using neuraminidase inhibitors against exposure to influenza virus has been well studied in household settings but not in nosocomial settings in pediatric wards.

Methods: We used oseltamivir or zanamivir as PEP in our pediatric wards. All influenza cases were diagnosed by the influenza rapid diagnostic test.

Results: Between 2003 and 2011, there were 20 nosocomial introductions of influenza (10 were A, 9 were B and 1 was undetermined). The index cases consisted of 17 inpatients, 2 parents and 1 medical staff member. The 17 inpatients had been admitted to the hospital for reasons other than infectious disease and they developed influenza after hospitalization. Among the 81 contacts, 28 (35%) were exposed to influenza A, and 52 (64%) were exposed to influenza B. The rate of secondary infection among contacts not given PEP was 29% (5/17), and the rate among contacts given PEP was significantly lower, 3% (2/63; P = 0.004). The 2 infected contacts who had been given PEP were both influenza B cases, and both had received oseltamivir. The contacts who received PEP within 24 hours (59), for influenza A (23) and those who received zanamivir (15) did not develop influenza. No adverse events were reported.

Conclusions: PEP using oseltamivir or zanamivir for unexpected occurrences of nosocomial influenza in pediatric wards is safe and effective. The influenza rapid diagnostic test that we used was helpful for detecting nosocomial influenza in children.


http://journals.lww.com/pidj/Abstract/2012/11000/Postexposure_Prophylaxis_for_Influenza_in.4.aspx
 
Back
Top Bottom